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The bioengineering of a replacement kidney has been proposed as an approach to 
address the growing shortage of donor kidneys for the treatment of chronic kidney 
disease. One approach being investigated is the recellularization of kidney scaffolds. 
In this study, we present several key advances toward successful re‐endothelializa‐
tion of whole kidney matrix scaffolds from both rodents and humans. Based on the 
presence of preserved glycosoaminoglycans within the decelullarized kidney scaf‐
fold, we show improved localization of delivered endothelial cells after preloading of 
the vascular matrix with vascular endothelial growth factor and angiopoietin 1. Using 
a novel simultaneous arteriovenous delivery system, we report the complete re‐en‐
dothelialization of the kidney vasculature, including the glomerular and peritubular 
capillaries, using human inducible pluripotent stem cell –derived endothelial cells. 
Using this source of endothelial cells, it was possible to generate sufficient endothe‐
lial cells to recellularize an entire human kidney scaffold, achieving efficient cell deliv‐
ery, adherence, and endothelial cell proliferation and survival. Moreover, human 
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1  | INTRODUC TION
Kidney transplantation is at present the best therapy for patients 
with end‐stage renal disease (ESRD). However, there is a shortage of 
donor organs, while the incidence of ESRD is increasing.1 Moreover, 
long‐term outcomes after kidney transplantation are compromised 
by the effects of rejection and nephrotoxicity of immunosuppres‐
sive therapies. An autologous bioengineered kidney with patient‐
derived cells would therefore constitute an attractive alternative. 
One proposed, but as yet unachieved, approach to generating such a 
replacement tissue is via the decellularization and subsequent recel‐
lularization of kidney matrix scaffolds.
Several considerations have to be taken into account when de‐
veloping a clinically applicable bioengineered kidney using such 
an approach. Recellularization should be performed with human 
cells, preferably patient‐derived or HLA‐matched. In addition, large 
numbers of cells are required for whole organ recellularization, and 
hence scalability is a major challenge. Human inducible pluripotent 
stem cell (hiPSC)–derived kidney and endothelial cells (ECs) are 
an interesting cell source for bioengineering, given their potential 
for expansion and possibility for autologous transplantation.2‐4 
However, the ultimate success of the approach will also rest with 
the capacity for a decellularized scaffold to support and instruct 
the delivered cells.
The first studies investigating the use of decellularized kidney 
scaffolds showed that the vascular compartment of rat kidney 
scaffolds can be recellularized with either primary ECs or mouse 
embryonic stem cells, some of which showed differentiation into en‐
dothelial phenotypes.5‐9 Such studies were performed with mouse 
and rat scaffolds and cells6; however, to date no bioengineering at‐
tempts have been performed using human kidney scaffolds recellu‐
larized with human cells.
This reflects the need for novel strategies to enhance endothelial 
coverage and the translation toward a human bio‐engineered kid‐
ney. For the lung, Ren et al described an extensive re‐endotheliali‐
zation study of scaffolds using human iPSC‐derived endothelial cells 
(hiPSC‐ECs) where combining arterial and venous infusion of both 
ECs and pericytes resulted in 75% re‐endothelialization.10 However, 
as the microvascular diameter in the glomeruli is low, combined in‐
fusion of ECs and relatively large pericytes in the kidney would most 
likely lead to obstructed glomerular arterioles and is therefore prob‐
ably less feasible for the kidney.
The major function of pericytes is the support of ECs via the local 
production of growth factors such as vascular endothelial growth 
factor (VEGF) and angiopoietin 1 (Ang‐1).10‐12 These factors are well 
known for their instructiveness for endothelial cell adherence, sur‐
vival, and differentiation10‐12 and often share the requirement of gly‐
cosaminoglycans (GAG) as extracellular matrix (ECM) components to 
exert their effects.13,14 Based on this knowledge, we hypothesized 
that, were GAGs maintained within the decellularized kidney matrix, 
preloading the kidney scaffolds with growth factors would provide a 
novel strategy to enhance endothelial localization without the need 
for co‐infusion of pericytes.
Here, we show an extensive characterization of the GAG landscape 
of the decellularized kidney, including the functional importance of 
these GAGs in growth factor binding. Human kidney scaffolds loaded 
with the growth factors VEGF and Ang‐1 did result in improved EC ad‐
herence and survival. Moreover, we describe several new optimized, 
scalable strategies to bioengineer the kidney vasculature from human 
iPSC‐ECs in a custom‐made perfusion‐culture system and provide a 
proof of concept for scaleup via the re‐endothelialization of a complete 
human decellularized kidney scaffold. Finally, we also show some func‐
tionality of the re‐endothelialized scaffold with whole blood perfusion.
2  | METHODS
2.1 | Whole organ decellularization of rat and 
human kidneys
All animal experiments were approved by the animal care and use 
committee of the Leiden University Medical Center. Research con‐
sent was given for all human kidneys. Rat and human kidneys were 
decellularized adapted from a protocol described previously.15
In short, 12‐week‐old Lewis rats (Charles River) were systemically 
heparinized with 5000 U heparin (Leo Pharma, Balledrup, Denmark) 
and the kidneys were flushed with University of Wisconsin (UW) cold 
storage solution (Bridge to Life, Elkhorn, WI) containing heparin (Leo 
Pharma). Kidneys were explanted and cannulated via the renal ar‐
tery and renal vein with a 24G Neoflon (Becton Dickinson Medical, 
Erembodegem, Belgium), and ureter with a 26G Neoflon (Becton 
Dickinson Medical) and perfused with 1% sodium dodecylsulfate (SDS) 
(w/v) (Sigma Aldrich, Zwijndrecht, the Netherlands) in PBS contain‐
ing 2% penicillin/streptomycin (Life Technologies, Europe Bleiswijk, 
the Netherlands), 6 μg/mL ciprofloxacin (Fresenius Kabi, Huis ter 
re‐endothelialized scaffold could, in contrast to the non‐re‐endothelialized human 
scaffold, be fully perfused with whole blood. These major advances move the field 
closer to a human bioengineered kidney.
K E Y W O R D S
basic (laboratory) research/science, kidney transplantation/nephrology, regenerative 
medicine, stem cells, tissue/organ engineering, translational research/science, vascular biology
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Heide, the Netherlands), 0.1% fungizone (w/v) (Bristol‐Myers Squibb, 
Utrecht, the Netherlands), and 2500E DNAse (pulmozyme, Roche, 
Woerden, the Netherlands) for 12 hours under a constant pressure of 
max. 50 mm Hg. Afterwards the kidneys were washed for 15 minutes 
with dH2O and perfused with 1% Triton‐X 100 (v/v) (Sigma Aldrich) for 
30 minutes. Then the kidneys were perfused with phosphate‐buffered 
saline (PBS) containing antibiotic/antimycotic for at least 48 hours and 
kept in this solution until use. Patency of both arterial and venous vas‐
cular beds was confirmed by methylene blue perfusion (Figure S1A).
Human transplant grade kidneys discarded mainly for surgical rea‐
sons were flushed with UW cold storage solution containing heparin 
directly after procurement and were stored on ice. Within 30 hours, 
kidneys were again flushed with PBS with heparin (500 IE/L) and the 
perirenal fat and kidney capsule were removed. The renal artery was 
cannulated with a Luer‐lock connector (Cole‐Parmer, Barendrecht, the 
Netherlands) and the kidney was perfused with 1% SDS in PBS contain‐
ing antibiotics, antimycotics, and DNAse as used with the rat kidneys, 
under a constant pressure of maximal 75 mm Hg for 5 days. Afterwards 
the kidneys were perfused overnight with dH2O with antibiotics, an‐
timycotics, and DNAse. Then the kidneys were flushed with 1% (v/v) 
Triton‐X 100 (Sigma) for 1 day and afterwards flushed with PBS with 
antibiotics and antimycotics for at least 5 days, all under a constant 
pressure of max. 75 mm Hg. Kidneys were stored at 4°C in PBS until 
further use. Samples of ≈1 cm3 were taken and either snap‐frozen in liq‐
uid nitrogen, fixed for paraffin embedding, or for electron microscopy.
2.2 | Proteomic analysis
Decellularized ECM samples were resolved by SDS–polyacrylamide 
gel electrophoresis (4% stacking and 10% running gel) and visualized 
by Coomassie staining. Protein bands were manually excised from the 
gel and subjected to in‐gel digestion by using a MassPREP digestion 
robot (Waters, Manchester, UK). Briefly, a solution of 50 mM ammo‐
nium bicarbonate in 50% v/v acetonitrile (ACN) was used for destain‐
ing. Cysteines were reduced with 10 mM dithiothreitol in 100 mM 
ammonium bicarbonate for 30 minutes followed by an alkylation re‐
action using 55 mM iodoacetamide in 100 mM ammonium bicarbo‐
nate for 20 minutes. Samples were washed with 100 mM ammonium 
bicarbonate and subsequently dehydrated with 100% ACN. Trypsin 
(6 ng/mL, Promega, Benelux Leiden, the Netherlands) in 50 mM am‐
monium bicarbonate was added and incubated at 37°C for 5 hours. 
Peptides were extracted using 1% v/v formic acid (FA) supplemented 
with 2% v/v ACN. A second extraction step was performed using 1% 
v/v FA supplemented with 50% v/v ACN.
Peptides were separated on a Thermo Scientific (Waltham, MA; 
Dionex) Ultimate 3000 Rapid Separation UHPLC system equipped 
with an Acclaim PepMap C18 analytical column (2 μm, 100Å, 
75 μm × 150 mm). Peptide samples were first desalted on an on‐
line installed C18 trapping column. After desalting, peptides were 
separated on the analytical column with a 90‐minute linear gradient 
from 5% to 35% ACN with 0.1% FA at a 300 nL/min flow rate. The 
UHPLC system was coupled to a Q Exactive HF mass spectrometer 
(Thermo Scientific) using full MS scan between 350 and 1650 m/z 
at a resolution of 120 000. Subsequent MS/MS scans of the top 15 
most intense ions were done at a resolution of 15 000. The obtained 
spectra were analyzed with the Proteome Discoverer (PD) software 
(version 2.2, Thermo Scientific) using the Sequest search engine and 
the SwissProt Human database (TaxID = 9606, v2017‐10‐25). The 
database search was performed with the following settings: trypsin 
digestion with a maximum of 2 missed cleavages, minimum peptide 
length of 6, precursor mass tolerance of 10 ppm, fragment mass tol‐
erance of 0.02 Da, dynamic modifications of methionine oxidation 
and protein N‐terminus acetylation, and static modification of cys‐
teine carbamidomethylation.
2.3 | Immunofluorescence stainings
Biopsies of de‐ and recellularized kidneys were fixed overnight in 4% 
formaldehyde (Klinipath, Duiven, the Netherlands), stored in 70% 
ethanol and embedded in paraffin. Four‐micrometer‐thick sections 
were cut and following rehydration of the tissue samples, antigen 
retrieval was performed by heating the slides in citrate buffer (pH 
6). Primary antibodies against laminin (Sigma‐Aldrich, Zwijndrecht, 
the Netherlands), collagenIV (NovusBio, Abingdon, UK), fibronec‐
tin (Abcam, Cambridge, UK), CD31 (Pharmingen), VEGF (Biovision, 
Zutphen, the Netherlands), and angiopoietin‐1 (Santa‐Cruz, Huissen, 
The Netherlands), were used. GAGs were shown with the lectins 
WGA (Invitrogen, Carlsbad, CA), LEA (Sigma‐Aldrich), heparan sul‐
fate specific antibodies (clone 10E4 [Amsbio]), and JM403 (Dr. J. 
van der Vlag, RadboudUMC, Nijmegen), and a fluorescent‐labeled 
hyaluronan‐specific binding protein neurocan‐GFP (custom made, 
adapted from previous published protocol16). As secondary anti‐
bodies, anti‐mouse, anti‐rat, and anti‐rabbit Alexa Fluor 488, 568, 
and 647 (Molecular Probes) were used. Nuclei were counterstained 
using Hoechst 33258 (ThermoFisher). Sections were imaged using 
SP8‐WLL confocal microscopy and displayed using LAS‐X software 
(Leica).
2.4 | Cell culture human glomerular microvascular 
endothelial cells
Human glomerular microvascular endothelial cells (hgMVECs) (Bio‐
connect, Huissen, the Netherlands) were cultured in EGM2 (Lonza, 
Breda, the Netherlands) in gelatin‐coated (Sigma‐Aldrich) T175 cul‐
ture flasks in a density of 2 million cells per flask.
2.5 | EC differentiation from hiPSCs and 
expansion method
Human pluripotent stem‐cell‐derived ECs were generated and ex‐
panded as described previously2 with minor adaptation for large‐
scale culture. In brief, hiPSCs (NCRM‐1) were cultured in TeSR‐E8 
medium (StemCell Technologies, Cologne, Germany) and passaged 
at day 4. For large‐scale culture the cells were passaged to T175 
cell culture flasks. Medium was refreshed at day 3 and at day 0 the 
differentiation started by Mesoderm induction medium consisting 
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of B(P)EL medium containing 30 ng/mL BMP4 (Miltenyi Biotec, 
Leiden, the Netherlands), 25 ng/mL Activin A (Miltenyi Biotec), 
1.5 μM CHIR99021 (Tocris Bioscience, Abingdon, UK), and 50 ng/mL 
VEGF165 (R&D Systems, Abingdon, UK). At day 3, medium was re‐
placed by vascular induction medium consisting of B(P)EL containing 
50 ng/mL VEGF and 10 μM SB431542 (Tocris Bioscience) and was 
refreshed again at days 7 and 9. At day 10, ECs were isolated with 
CD31‐dynabeads (Invitrogen) and the CD31‐positive fraction was 
cultured in EC‐SFM medium (GIBCO, Carlsbad, CA) on gelatin‐coated 
(Sigma‐Aldrich) T175 cell culture flasks. Cells were either replated 
(1:3) or cryopreserved when the flask is fully confluent after isola‐
tion. CD31, VE‐CAD, Tie2, and VEGFR2 (R&D Systems) immunofluo‐
rescence was stained as described above on hiPSC‐ECs cultured on 
coverslips and fixed with 4% paraformaldehyde (PFA). Before recel‐
lularization experiments, cells were thawed using standard protocols 
and reseeded in gelatin‐coated T175 cell culture flasks with EC‐SFM. 
Recellularization was performed with hiPS‐EC at passage 2‐3.
2.6 | Acetylated low‐density lipoprotein assay
HiPSC‐ECs and hgMVECs were cultured in gelatin coated 6‐well plates 
for 12 hours until they reached 30%‐40% confluency. HiPSC‐ECs and 
hgMVECs were serum starved for 48 hours in SFM‐EC (without sup‐
plemental growth factors but with 0.3% bovine serum albumin [BSA]) 
and EGM (without serum but with 0.3% BSA), respectively. Afterwards, 
the labeled low‐density lipoprotein (LDL) was diluted in wash buffer 
(150 mg BSA in HBSS) to a final working concentration of 6.7 μg/mL 
and added to the medium used for cell incubation. After 4 hours, cells 
were washed with wash buffer and fixed with 4% PFA and nuclei were 
counterstained using Hoechst 33258 (ThermoFisher). Sections were 
imaged using SP8‐WLL confocal microscopy and displayed using LAS‐X 
software (Leica). Quantification was performed using ImageJ software 
by calculating the average number of positive particles per cell.
2.7 | Growth factor loading scaffolds
Slices (20 μm) of cryopreserved tissue of 3 different human decellu‐
larized kidneys were made with a microtome and placed on a 18‐mm 
coverslip in 24‐well plates (Corning, Amsterdam, the Netherlands). 
All experiments were performed with 3 slices per kidney of 3 differ‐
ent donor kidneys. When indicated, scaffold slices were incubated 
with either 100 UI/mL hyaluronidase (Sigma‐Aldrich) or 1/0.6 UI/mL 
Heparinase I/HeparinaseIII (Sigma‐Aldrich) and protease inhibitor 
(ThermoFisher) for 4 hours at 37°C. Samples were washed 3 times 
with PBS and coated with, respectively 0, 10, 100, and 1000 ng/
mL VEGFA 165 (PreproTech, London, UK) or Ang1 (R&D systems) 
in PBS overnight at 4°C. Samples were fixed with 4% paraformal‐
dehyde (Klinipath, Duiven, the Netherlands) in PBS before stain‐
ing. Scaffolds were stained for, respectively VEGF, heparan sulfates 
(10E4), Ang1, and laminin as described above and images of 2 areas 
per slide of 3 different kidney scaffolds were taken with confocal 
microscopy (Leica TSC SP8 WLL). Maximum intensity was analyzed 
in LAS‐X software (Leica).
2.8 | EC adherence to human kidney scaffold
hgMVECs and iPS‐ECs were incubated on human kidney slices 
placed on coverslips in a concentration of 50 000 cells per well in 
a 24‐well plate. hgMVECs were cultured in EBM (Lonza) and iPS‐
ECs were cultured in EC‐SFM without VEGF. Cells were incubated 
on scaffold slices for 24 hours and afterwards fixed with 4% para‐
formaldehyde (Klinipath) in PBS for 10 minutes and washed 3 times 
with PBS. Slices were stained for CD31 and laminin, analyzed with 
fluorescence microscopy (Zeiss LSM500) (3 areas per slide), and the 
CD31/laminin ratio was determined in triplicates (Image J).
2.9 | Whole organ recellularization set‐up
The recellularization set‐up contained a sterilized custom‐made air‐
tight organ chamber, sterilized perfusion tubes (LS13 for rat kidneys 
and LS25 for human kidneys) (Masterflex [Metrohm], Barendrecht, 
the Netherlands), a pressure probe (Edwards Lifesciences, Breda, 
the Netherlands), and a custom‐made pressure controller. Pressure‐
driven perfusion was achieved with a Masterflex pump. For gas 
exchange, 3.35/4.65‐mm silicon tubes (Helixmark, Freudenberg 
Medical, Würselen, Germany) were used. At the end of the silicon 
tubing a filter was attached as a bubble trapper (Millex‐FG, 0.20 μm, 
Merck, Amsterdam, the Netherlands). The cannulated kidney artery, 
vein, and ureter were connected to 3‐way taps (Discofix, Braun, Oss, 
the Netherlands). A 3‐way tap with an inlet tube (LS‐13) for the cells 
was placed. A negative pressure of −30 mm Hg was achieved by at‐
taching a filter (Millex‐FG, 0.20 μm, Merck) and LS‐25 (Masterflex) 
to the airtight chamber with a pressure probe (Edwards Lifesciences) 
and a custom‐made pressure controller.
2.10 | Re‐endothelialization of rat kidney scaffolds 
with hgMVEC
Rat decellularized kidneys were placed in custom‐made organ 
chambers and perfused overnight with 1000 ng/mL VEGF in EBM2 
basal medium (Lonza) in a recellularization loop. Afterwards kidneys 
were flushed with fresh EGM2. During recellularization, the organ 
chamber pressure was set to 30 mm Hg via a pressure‐controlled 
Masterflex pump. For arterial infusion (n = 1), 30 million cells were 
resuspended in 15 mL medium and placed in an infusion bag (Transfer 
pack, 600 mL, Fenwall Inc. [Baxter] Utrecht, the Netherlands) on a 
shaker plate and infused into the renal artery at an average flow of 
90 μL/min into the recirculation loop under a maximum pressure of 
175 mm Hg. The bag was flushed with 5 mL medium and 30 mL of 
medium was added to the organ chamber. Medium was recirculated. 
For venous infusion (n = 1), 30 million cells were infused via the renal 
vein at a flow of 1.2 mL/min at a maximum pressure of 20 mm Hg. 
For arterial and venous infusion (n = 4), 20 million cells were resus‐
pended in 7.5 mL EGM2 and infused into the renal vein at an average 
flow of 600 μL/min under a maximum pressure of 20 mm Hg. The 
bag was flushed with 5 mL medium. Cells were recirculated through 
the renal vein for 3 hours and then 10 million cells were infused 
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in 5 mL EGM2 over the renal artery with a maximum pressure of 
75 mm Hg and recirculated followed by 5 mL of EGM2. Medium 
was refreshed daily and the maximum pressure was kept at 100 mm 
Hg. Recellularized kidneys were perfused with live cell Hoechst 
(ThermoFisher) and harvested after 48 hours. Half of the kidney was 
fixed in PFA and placed in paraffin. The other half was snap frozen 
in liquid nitrogen. When indicated, hgMVECS were first labeled with 
Qtracker625 and Qtracker705 according to manufacturer's proto‐
col (ThermoFisher) and imaged using second harmonics generation 
(SHG) on a multiphoton microscope (Zeiss, Breda, the Netherlands).
2.11 | Re‐endothelialization of rat kidney scaffolds 
with hiPSC‐derived ECs
The protocol used for whole organ recellularization with hiPSC‐de‐
rived EC is comparable to the combined arterial and venous recel‐
lularization with hgMVECs with the exception that instead of EGM2, 
the kidney is perfused with EC‐SFM. Kidneys were perfused either 
under a constant pressure of maximal 75 mm Hg or when the flow 
was >1.2 mL/min a constant flow of 1.2 mL/min.
Medium was refreshed daily and recellularized kidneys were har‐
vested either 48 hours (n = 3), 5 days (n = 2), or 13 days (n = 2) after 
recellularization as indicated.
2.12 | Re‐endothelialization of human kidney 
scaffold with hiPSC‐derived ECs
A decellularized human kidney was perfused overnight with 1 μg/
mL VEGF and 1 μg/mL Ang1 in EC‐SFM at a pressure of 50 mm 
Hg, resulting in a flow of 27 mL/min. Afterwards the kidney was 
perfused with fresh EGM2. Next the chamber pressure was set 
to −30 mm Hg and 60 million cells were infused via the renal vein 
at 20 mL/min flow and kept in a recirculation loop for 3 hours. 
Afterwards 70 million cells were infused via the renal artery at 
a 20 mL/min flow. The chamber pressure was changed to 0 mm 
Hg and the kidney was perfused via the renal artery at a flow of 
20 mL/min for 24 hours, resulting in a pressure of 35‐50 mm Hg. 
Biopsies of 1 cm3 were taken out of 10 different areas of the kid‐
ney cortex, medulla, and papilla and were either snap frozen or 
fixed in 4% paraformaldehyde and paraffinized.
F I G U R E  1   Decellularized human kidneys show intact integrity and glycosaminoglycan (GAG) landscape. A, Macroscopic pictures of 
human kidney before (left) and after (right) decellularization. B, Scanning electron microscopy (SEM) images of decellularized human kidney 
show preservation of tissue architecture after decellularization. C, Detailed SEM image of a decellularized glomerulus. D, Extracellular matrix 
components are preserved as shown by hematoxylin, collagen IV, fibronectin, and laminin staining of human decellularized kidneys (lower 
panels) compared to native kidney (upper panels). E, The GAG landscape of the human kidney is preserved after decellularization as depicted 
by WGA, LEA, 10E4 (heparan sulfates), JM403 (heparan sulfates), and neurocan‐eGFP (hyaluronan) stainings. eGFP, enhanced green 
fluorescent protein; GAG, glycosaminoglycan; LEA, lectin from Lycopersicon esculentum; WGA, wheat germ agglutinin. Scale bar B, C 10 μm; 
D, E 100 μm [Color figure can be viewed at wileyonlinelibrary.com]
     |  1333LEUNING Et aL.
2.13 | Quantification of endothelial coverage and 
proliferation
All recellularized kidneys were deparaffinized and immunohis‐
tochemically stained with CD31 and Ki‐67 (BD Pharmingen) fol‐
lowed by rabbit anti‐mouse‐HRP (DAKO, Heverlee, Belgium) and 
NovaRed (Vector Labs, Burlingame, CA) and imaged in a slide 
scanner (3D Histech). From the recellularized rat kidneys, 1 com‐
plete slide per kidney was analyzed. From the human recellular‐
ized kidneys, slides of 4 different areas of the kidney cortex were 
analyzed. From the normal human kidney, control slides of 3 dif‐
ferent areas were analyzed. For Ki‐67 quantification, all positive 
Ki‐67 nuclei were annotated and counted manually. Percentages 
are given as % of all Hoechst + cells.
For CD31 quantification, all glomeruli within the cortex slides 
were annotated manually and the amount of filled glomeruli per 
kidney is depicted in the graph column as % of all glomeruli present. 
The % of CD31+ area within these filled glomeruli was then calcu‐
lated using HistoQuant software.
For cortex, medulla, and papilla CD31+ area analysis, the entire sub‐
sequent area was annotated and % CD31+ was calculated as percent‐
age of total annotation area using HistoQuant software.
2.14 | Perfusion of human re‐endothelialized 
scaffolds with whole blood
Human whole blood (150 mL) was collected from a venous line and 
anticoagulated with natrium citrate (0.11 M). The tubing was coated 
with heparin (1000 U/mL) and human serum albumin (10%) (2 hours), 
fixated with glutaraldehyde 10% (20 minutes), and washed with PBS 
(2 hours) before use. Calcium (10 mM CaCl2) was added to the blood 
right before perfusion. Blood was perfused through both kidneys with 
Core matrisome Matrisome‐associated
Glycoproteins Collagens ECM‐regulator Extracellular space
AZGP1 COL1A1 AMBP AGRN
DPT COL1A2 APOA4 ANXA1
EFEMP1 COL21A1 CPB2 ANXA2
ELN COL3A1 F9 APCS
EMILIN1 COL4A1 ITIH3 C4BPA
FBLN2 COL4A2 LTF CLEC18B
FBN1 COL4A3 LYZ CLU
FGA COL4A4 MGP DCD
FN1 COL4A5 PRSS1 DEFA1/B
HRG COL4A6 PRSS23 IGHG4
LAMAS COL5A1 SERPINA3 IGKC
LAMB1 COL5A2 SERPINE2 INHBC
LAMB2 COL5A3 SERPINB12 INHBE
LAMC1 COL6A1 SLPI LTBP1
MFAP4 COL6A2 SPP2 MFAP2
NIDI COL6A3 THSD4 MFAP5
NID2 COL7A1 TIMP3 MFGE8
POSTN COL8A1 NPNT
TGFBI COL10A1 PDGFB
TNC COL11A1 PPIA
VTN COL12A1 PROM1
COL14A1 PSAP
Proteoglycans COL18A1 SEMA3G
BGN TNFSF12/3
FLNC
LUM Secreted factors
PRELP S100A9
HSPG2 S100A8
ECM, extracellular matrix.
TA B L E  1   Matrisome analysis of a 
decellularized human kidney scaffold 
shows preservation of both major ECM 
compounds as well as matrisome‐
associated proteins and proteoglycans
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F I G U R E  2   Growth factor loading of the kidney scaffolds results in increased endothelial cell adherence and survival. A, Slices of human 
kidney scaffold can be loaded with VEGFA 165, which is heparan sulfate dependent. B, Quantification of VEGF loading capacity shows 
enhanced VEGF binding after VEGF loading. C, Scaffolds can also be loaded with Ang1, independent of heparan sulfates and hyaluronan. 
D, Quantification of Ang1 binding. E, Representative images of CD31 staining after 24‐h culture of hgMVEC on VEGF loaded scaffolds 
showing enhanced endothelial cell adherence and survival after VEGF loading, which was not observed after removal of heparan sulfates. 
F, Quantification of re‐endothelialization after VEGF loading. G, Representative images of hgMVEC culture on Ang1‐loaded scaffolds show 
enhanced endothelial cell adherence and survival after Ang1 loading. H, Quantification of hgMVEC adherence and survival after Ang1 loading. 
Ang1, angiopoietin 1; hgMVEC, human glomerular microvascular endothelial cells; ns, nonsignificant; 10E4, heparan sulfates; VEGF, vascular 
endothelial growth factor A 165. *P < .05, ***P < .001, ****P < .0001. Scale bars 100 μm [Color figure can be viewed at wileyonlinelibrary.com]
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F I G U R E  3   A novel arteriovenous delivery system for whole organ tissue engineering. A, Kidney matrices were cultured in custom‐made 
organ chamber as shown in front view and (B) side view. C, Schematic representation of recellularization set‐up. D, Image of recellularization 
set‐up. E, Representative images after whole organ recellularization of hgMVECs. Infusion via only the artery shows obstruction of the 
afferent arteriole and glomeruli, via only the vein shows re‐endothelialization of the peritubular capillaries in both the cortex and medulla 
and some glomeruli while combined infusion show re‐endothelialization of both peritubular capillaries and glomeruli. F, Representative 
live‐cell images with differential Qdot labeling and SHG show re‐endothelialization of peritubular capillaries and part of the glomeruli via the 
renal vein (Qdot 625, green) while the afferent arteriole and the glomeruli were re‐endothelialized via the renal artery (Qdot 705, red). SHG, 
second harmonics generation; recirc, recirculation; A, arterial inlet; V, venous inlet; U, ureteric inlet; p, pressure sensor. Scale bars 100 μm 
[Color figure can be viewed at wileyonlinelibrary.com]
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a constant flow of 15 mL/min, while the pressure (mean arterial pres‐
sure in mm Hg) was constantly measured. Afterwards, 1‐cm3 samples 
were taken out of different areas of the kidney cortex, medulla, and 
papilla and were either snap frozen or fixated in 4% paraformaldehyde. 
Paraffinized samples were deparaffinized and immunohistochemically 
stained with Movat‐Pentachrome staining.
2.15 | Transmission electron microscopy
Small pieces (≈1 mm2) of recellularized kidney scaffold were fixed 
overnight at 4°C in 1.5% glutaraldehyde (Electron Microscopy 
Sciences) in 0.1 M sodium‐cacodylate buffered solution, with 
a pH of 7.4. Afterwards, the tissue blocks were washed twice 
with sodium cacodylate buffer, then fixed in 1% osmium tetrox‐
ide (Electron Microscopy Sciences) in 0.1 M sodium cacodylate 
buffer for 1 hour. Samples were further rinsed twice with 0.1 
M sodium‐cacodylate buffer, followed by dehydration steps of 
70% ethanol (overnight), 80% ethanol (10 minutes), 90% etha‐
nol (10 minutes), and 100% ethanol absolute (2 × 15 minutes; 
1 × 30 minutes).
The probes were subsequently infiltrated with a mixture of 
1:1 Epon LX‐112 (Ladd Research, Williston, VT) and propylene 
oxide (Electron Microscopy Sciences) for 1 hour, then with pure 
Epon for 2 hours, embedded in pure Epon, mounted in BEEM 
plastic capsules (Agar Scientific, Essex, UK), and polymerized for 
48 hours at 60°C. Ultrathin sections of 100 nm were collected on 
copper slot grids (Storck Veco B.V., Eerbeek, The Netherlands), 
covered with formvar film and a 7‐nm carbon layer. The sections 
were stained afterwards with an aqueous solution of 7% uranyl 
acetate (20 minutes), followed by Reynold's lead citrate (10 min‐
utes). Samples were analyzed at an acceleration voltage of 120 kV 
with an FEI Tecnai 12 transmission electron microscope (FEI, 
Eindhoven, The Netherlands), equipped with a FEI 4k Eagle CCD 
camera.
F I G U R E  4   Scalability of hiPS‐EC culture and ability to adhere to growth‐factor‐loaded scaffolds. A, Adjusted hIPS‐EC differentiation 
protocol where large quantities of hIPS‐ECs can be obtained. B, Representative images of hiPS‐ECs show positivity for vascular endothelial 
markers CD31, VE‐cadherin, VEGF‐receptor 2, and Tie2. C, Representative images of hiPSC‐EC adherence and survival after VEGF, Ang‐1, 
or combined loading of the scaffold. D, Quantification of hiPS‐EC adherence after VEGF, Ang‐1, and combined loading. Ang‐1, angiopoietin 
1; PBS, phosphate‐buffered saline; hiPS‐ECs, human inducible pluripotent stem cell–derived endothelial cells; VEGF, vascular endothelial 
growth factor. Scale bar 50 μm [Color figure can be viewed at wileyonlinelibrary.com]
     |  1337LEUNING Et aL.
2.16 | Scanning electron microscopy
Tissue samples were fixed and dehydrated using the same protocol as for 
transmission electron microscopy. The 100% ethanol absolute dehydra‐
tion step was followed by critical point drying. Afterwards, the probes 
were further mounted on 0.5” scanning electron microscopy (SEM) pin 
stubs (Agar Scientific, Essex, UK) covered with conductive carbon discs 
(Agar Scientific), and coated with gold‐palladium. Images were acquired 
with a JEOL JSM‐6700F Field Emission Scanning Electron Microscope 
(JEOL Europe BV, Nieuw‐Vennep, the Netherlands).
2.17 | Statistical analysis
Statistical analysis was performed using ANOVA analysis with 
Bonferroni's post hoc comparison. Differences were considered sta‐
tistically significant when P < .05. Values in graphs are presented as 
means with standard deviation. Data analysis was performed using 
GraphPad Prism, version 7.02 (Graphpad Prism San Diego, CA).
3  | RESULTS
3.1 | Perfusion‐decellularized human kidneys show 
preservation of microarchitecture and major ECM 
components including glycosaminoglycans
Rat and human transplant grade kidneys were decellularized via the 
renal artery with 1% SDS followed by 1% Triton‐X100 as described pre‐
viously15 (Figure 1A). Tissue micro‐architecture was preserved as shown 
with SEM (Figure 1B,C). The ECM proteome was preserved as indicated 
by the mass spectrometry analysis performed on human decellular‐
ized transplant grade kidneys. Ninety‐two proteins comprising 49 core 
matrisome proteins (21 ECM glycoproteins, 23 collagens, and 5 proteo‐
glycans) and 43 matrisome‐associated proteins (17 ECM‐regulators, 24 
extracellular space, and 2 secreted factors) were identified (Table 1). In 
addition, histology of the decellularized human kidneys showed pres‐
ervation of ECM components collagen IV, fibronectin, and laminin with 
complete removal of nuclei (Figure 1D). Moreover, GAGs including 
heparan sulfates and hyaluronan were preserved (Figure 1E). GAGs are 
expressed on several different compartments in the kidney including 
the extracellular membranes but also within the tubular brush borders. 
Because of the latter, the total amount of GAG expression seen after 
decellularization diminishes due to the removal of the tubular brush 
borders. Glycosaminoglycans contain different epitopes, which can be 
demonstrated by staining with different antibodies (such as 10E4 and 
JM403). JM403 specifically recognize the nonsulfated domain, whereas 
10E4 is specific for epitopes of the core protein.17‐19 Similar histology 
results were obtained with rat decellularized kidneys (Figure S1).
3.2 | Decellularized human kidney matrix can be 
loaded with vascular growth factors through binding 
to GAGs
As GAGs are still preserved after the decellularization method 
used, and GAGs are important for growth factor binding, we 
analyzed whether vascular growth factors can still bind to these 
GAGs. Indeed, we were able to load both the glomerular and tu‐
bular compartment of human kidney scaffold slices from 3 differ‐
ent donors with recombinant VEGFA 165, which localized to the 
heparan sulfates in the ECM (Figure 2A,B). Moreover, removal of 
heparan sulfates by heparinase treatment led to lower VEGF bind‐
ing to the scaffold, while hyaluronidase treatment did not influ‐
ence VEGF binding (Figure 2B and Figure S2). This indicates that 
the binding of VEGF to the scaffold is dependent on heparan sul‐
fates and the binding domain of VEGF.14,20 Kidney scaffolds from 
3 different donors could also be loaded with Ang‐1 (Figure 2C,D). 
In this case, Ang‐1 binding did not appear to be dependent upon 
the presence of the GAGs hyaluronan and heparan sulfate because 
enzymatic removal of these GAGs did not decrease Ang‐1 binding 
(Figure 2D).
3.3 | Growth factor loading is critical for EC 
adherence and survival on the human kidney matrix
The functional effects of growth factor loading on EC adherence and 
survival to the kidney matrix were analyzed. For this purpose, hgM‐
VEC were cultured on slices of human kidney scaffolds in triplicate 
with or without VEGF loading (Figure 2E). An increase in EC adher‐
ence and survival was observed on VEGF‐loaded scaffolds com‐
pared to nonloaded scaffolds, as quantified in Figure 2F. Removal 
of heparan sulfates led to a decreased endothelial cell adherence in 
line with the decreased VEGF binding (Figure 2F). Ang‐1 loading also 
increased hgMVEC cell adherence and survival (Figure 2G,H). These 
data illustrate the importance of the growth factor binding capacity 
of the scaffold for EC adherence and survival, and are a novel strat‐
egy to enhance revascularization.
3.4 | Combined arterial and venous recellularization 
in whole kidney scaffold is the best strategy to 
achieve an in situ bioengineered kidney vasculature
For whole kidney scaffold recellularization, a custom‐made, air tight, 
sterilizable organ culture chamber was developed. This chamber was 
designed in such a way that optimal recirculation of medium with‐
out air infusion could be achieved (Figure 3A,B). This organ culture 
chamber was connected to a pressure‐controlled perfusion system, 
allowing separate recellularization of the arterial, venous, and ure‐
teric compartments (Figure 3C,D). Different infusion protocols, via 
the artery, the vein, or first the vein followed by the artery after 
3 hours were compared. Using this device, hgMVECs were infused 
into either the artery or vein, or both the arterial and venous arm 
of the vasculature of growth factor loaded rat kidney scaffolds and 
scaffolds were then analyzed after 48 hours of culture. As shown 
in Figure 3E, arterial perfusion of the cells led to large obstructions 
in the afferent arterioles in the cortex, while hardly any cells were 
observed in the medulla and papilla (Figure 3E). In contrast, ve‐
nous infusion of cells led to re‐endothelialization of the peritubu‐
lar capillaries in both the cortex and medulla with some glomerular 
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re‐endothelialization (Figure 3E). The combination of arterial and ve‐
nous perfusion showed both glomerular and peritubular re‐endothe‐
lialization. No cells were observed in the tubular compartment, as 
shown with laminin‐CD31 double staining, confirming that the base‐
ment membrane remains intact after cell infusion. While arterial and 
venous infusion separately resulted in low glomerular re‐endothe‐
lialization, combined infusion increased the glomerular coverage. 
Compared to arterial infusion, combined infusion also resulted in an 
increase of medullary re‐endothelialization; however, there were still 
some obstructed afferent arterioles observed (Figure 3E). In order to 
trace hgMVECs administered into either the arterial or venous arm 
of the vasculature, hgMVECs were labeled with 2 different Qdots. 
Live‐cell imaging with second harmonics generation (SHG) showed 
that peritubular capillaries and part of the glomeruli were re‐en‐
dothelialized via the renal vein while the afferent arteriole and the 
glomeruli were re‐endothelialized via the renal artery (Figure 3F).
3.5 | Induced pluripotent derived ECs are able to 
adhere to and survive on growth factor loaded human 
kidney scaffolds
Optimal bioengineering of an autologous replacement human kid‐
ney would require large numbers of human or patient‐derived cells. 
In order to achieve this, we examined whether human iPSC‐ECs 
(hiPSC‐ECs) are a suitable candidate for re‐endothelialization of 
the kidney scaffold. In order to obtain large quantities of hiPSC‐
ECs, a previously described hiPSC‐EC differentiation protocol2 was 
adjusted for large‐scale production by increasing the culture sur‐
face during differentiation from a 6‐well plate format toward the 
use of multiple T175 cell culture flasks (Figure 4A). The resulting 
cells expressed the endothelial differentiation markers CD31 and 
VE‐cadherin, and were positive for both VEGF receptor 2 and Tie2 
(Figure 4B), suggesting that they will be responsive to VEGF and 
Ang‐1. Ninety‐seven percent of the cells were CD31 positive after 
dissociation as shown by FACS analysis in Figure S3A. Moreover, 
iPS‐ECs showed similar acetylated LDL uptake compared to hgM‐
VECs as is shown in Figure S3B. In agreement, VEGF loading of the 
scaffold resulted in increased adherence and survival of hiPSC‐ECs 
on human kidney scaffold slices (Figure 4C). A similar trend was 
observed with Ang‐1‐loading and combined loading (Figure 4C) as 
quantified in Figure 4D.
3.6 | Rat whole kidney scaffold re‐
endothelialization with hiPS‐ECs
Growth factor–loaded decellularized rat kidneys were recellular‐
ized with hiPSC‐ECs via both the renal artery and vein as described 
above. Indeed, after 48‐hour re‐endothelialization of the glomeruli, 
the larger vessels and peritubular capillaries in both the cortex and 
medulla were observed (Figure 5A,B).
Analysis of CD31+ was performed on the re‐endothelialized rat 
kidneys, which showed that 70% of all the glomeruli at 2 days and 
33% after 13 days contained ECs. Within these filled glomeruli, about 
5% of CD31+ area was observed at 2 days (Figure 5C). The total 
cortex contained ≈8.9% CD31+ area after 2 days (Figure 5D). After 
13 days, the amount of CD31+ area is 4.2%, which is, although not 
1:1 comparable, similar in normal human kidney (3.3%) (Figure 5C,H).
Moreover, 7.8% of proliferating hiPS‐ECs could be observed 
48 hours after recellularization, as illustrated by the Ki67 staining in 
Figure 5G. Transmission electron microscopy showed alignment of 
the hiPSC‐ECs on the endothelial side of the glomerular basement 
membrane (Figure 5E). Moreover, alignment within larger vessels 
was also observed (Figure 5F). Cells remained viable for the maximal 
duration of the current experiments (up to 13 days) where 36% of 
cells were still proliferating (Figure 5H).
3.7 | Human whole kidney scaffold re‐
endothelialization using hiPSC‐ECs
In order to evaluate whether this recellularization method would also 
be feasible for the much larger human kidneys, we performed 2 inde‐
pendent experiments where we re‐vascularized a growth factor loaded 
human decellularized kidney with 6 × 107 hiPSC‐ECs via the renal vein 
followed by 7 × 107 hiPSC‐ECs via the renal artery and cultured the kid‐
ney for 24 hours (Figure 6A). As shown in Figure 6B and C, we were able 
to re‐endothelialize the cortex, medulla, and papilla. Representative 
immunofluorescent images of EC alignment respectively in the cortex 
(Figure 6D), larger arteries (Figure 6E), medulla (Figure 6F), and papilla 
(Figure 6G) are shown. hiPSC‐ECs were able to proliferate in the human 
kidney scaffold (9.6% of the hiPSC‐ECs), as shown by Ki‐67 staining 
Figure 6H. Analysis of CD31+ in 4 biopsies taken from different loca‐
tions through the kidney cortex showed that more than 80% of the 
glomeruli contained ECs. Within these glomeruli, 3.8% of the area was 
F I G U R E  5   Re‐endothelialization of rat decellularized kidney matrices with hiPS‐ECs. A, Whole organ image of CD31+ in the whole 
re‐endothelialized rat kidney scaffold. B, Representative images after hiPS‐EC recellularization showing re‐endothelialization in the cortex, 
including the glomeruli, the medulla/papilla, and in the larger vessels. C, Quantification of CD31 positivity. For the recellularized rat kidneys 
(N = 2‐3) 1 complete slide per kidney was analyzed. Per slide all glomeruli were annotated manually (about 100 glomeruli per slide). The 
graph displays the amount of filled glomeruli as a % of all glomeruli per kidney (left) and the % of CD31+ area within all filled glomeruli (right) 
for 2 and 13 days after recellularization. ****P < .0001 *P < .05. D, For cortex analysis %CD31+ area was calculated within whole cortex area 
per kidney. E, TEM image of a glomerulus shows alignment of endothelial cells on the endothelial side of the GBM. F, TEM image showing 
alignment in a larger vessel. G, Representative image of Ki67 staining showing proliferating hiPS‐ECs in both the cortex and medulla. H, 
Representative image of CD31 positivity after 13 days of culture in both the cortex and medullary/papillary region. BF, bright field. Scale bar 
B, E, F 50 μm. Scale bar C, D 5 μm. Dashed line: aligning endothelial cell, black/white arrow: CD31 dynabeads, which are used for hiPS‐ECs 
isolation, black arrow: remaining extracellular matrix between foot processes on podocyte side of the GBM. GBM, glomerular basement 
membrane; hiPS‐ECs, human inducible pluripotent stem cell–derived endothelial cells; TEM, transmission electron microscopy
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positive for CD31, which is close to the area observed in normal human 
kidney (6.7%; Figure 6I). The observed CD31+ area within the cortex 
was 3.0%, which is also similar to the normal human kidney (3.3%; 
Figure 6J). Obstructed blood vessels within the recellularized scaffold 
were minimal (area < 0.03%). This indicates that our re‐endothelializa‐
tion method is scalable to the level of an entire human kidney scaffold.
3.8 | Human re‐endothelialized kidney scaffold can 
be perfused with human whole blood
In order to show some functionality of the re‐endothelialized human 
kidney scaffold, both re‐endothelialized and decellularized kidney scaf‐
folds were perfused with human recalcified whole blood. Using the de‐
cellularized kidney, the maximum mean arterial pressure measurable 
(>200 mm Hg) was reached within 5 minutes after whole blood perfu‐
sion and no more perfusion was possible due to clothing and massive 
leakage along the cannula. In contrast, the re‐endothelialized scaffold 
could be perfused for more than 20 minutes with only a moderate in‐
crease in mean arterial pressure (Figure 6O). In order to preserve the 
ECs in the scaffold for immunohistochemical analysis, the perfusion 
was stopped after 25 minutes when pressure stabilized. After per‐
fusion, major differences in both macroscopic (Figure 6K and L) and 
microscopic (Figure 6M,N) appearance of the whole blood perfused 
kidneys were observed. Whereas the perfused decellularized kidney 
only showed some “patchy” blood‐perfused areas, the perfused re‐en‐
dothelialized kidney showed a more diffuse and complete coverage 
with whole blood. These results suggest that re‐endothelialization of 
the kidney scaffolds leads to less clotting, resulting in lower inflow pres‐
sures and a better distribution of human whole blood when perfused.
4  | DISCUSSION
The current study shows that, by using hiPSC‐ECs combined with 
growth factor loading and a differential arteriovenous delivery 
system, it is possible to reconstitute both the macro‐ and microvas‐
cular compartments of a human kidney scaffold. The improved de‐
livery via simultaneous arterial and venous infusion, coupled with 
enhanced cellular localization and adherence due to growth factor 
preloading, resulted in a significant improvement in endothelial cov‐
erage of the delivered cells within the scaffold. In combination, these 
represent significant advances in the use of decellularized kidney 
scaffolds as a platform for kidney bioengineering.
The decellularization protocol used preserved both core matrix 
proteins as well as matrisome proteins (Table 1). Previously Peloso 
et al showed preservation of some growth factors in human kidney 
scaffolds postdecellularization, including low levels of VEGF.21 Using 
our protocol, however, presence of both VEGF and Ang‐1 were low 
after decellularization while at the same time the GAG landscape 
appeared to be preserved. The latter offered the possibility to re‐
constitute the growth factors on the kidney ECM as a novel strategy 
to increase EC localization. Our data show that such a step is critical 
for cell adherence and survival, and it appeared to be a key step in 
facilitating maximal coverage which in turn improved the feasibility 
of scaleup for re‐endothelialization of a human‐size kidney scaffold. 
As both Ang‐1 and VEGF exert different effects on EC adherence, 
proliferation, and survival, we chose to load the kidney scaffolds 
with both factors in order to achieve optimal conditions for recel‐
lularization. We showed that this method resulted in sufficient en‐
dothelial coverage to accomplish whole blood perfusion of a human 
re‐endothelialized kidney scaffold.
Alternative strategies to enhance re‐endothelialization have 
also been described, including combined infusion of ECs and peri‐
cytes in the lung10 and CD31‐conjugation in the kidney.22 In the 
latter, CD31 antibody conjugation resulted in enhanced re‐endo‐
thelialization in porcine kidney scaffolds to similar levels as re‐
ported here. However, revascularization was performed using a 
murine EC line.
Our study, therefore, also underscores the potential of 
human pluripotent stem cells as a source of human endothelium. 
F I G U R E  6   Human kidney re‐endothelialization with hiPS‐ECs. A, Image of the human re‐endothelialized kidney in the custom‐made 
organ chamber during culture. B, Representative immunohistochemistry images of CD31+ showing re‐endothelialization in the cortex, 
medulla, and (C) papilla. D, Representative CD31 immunofluorescent images show re‐endothelialization of the kidney cortex, (E) artery, 
(F) medulla, and (G) papilla. CD31 dynabeads used in the iPS‐EC differentiation protocol (white arrowheads) can still be observed. H, 
Representative image of proliferating cells in the human re‐endothelialized kidney. I, Quantification of CD31. For the recellularized human 
kidneys (N = 2) 4 areas per kidney were sampled and analyzed. Per slide all glomeruli were annotated manually (about 100 glomeruli per 
slide). The graphs display the amount of filled glomeruli as a % of all analyzed glomeruli per kidney (left) and the % of CD31+ area within 
all filled glomeruli (right) at 24 h after infusion of cells. ****P < .0001 **P < .01. J For cortex analysis %CD31+ area was calculated within 
whole cortex area per kidney. The graphs display the average of 4 different sample areas per kidney. ****P < .0001. K, Macroscopic image 
of a decellularized human kidney perfused with whole blood showing only some “patchy”perfused areas. L, Macroscopic image of a re‐
endothelialized human kidney scaffold perfused with whole blood showing diffuse blood coverage over the whole kidney. M, Microscopic 
picture of a Movat's‐Pentachrome staining of a decellularized human kidney cortex scaffold perfused with whole blood shows only a 
few perfused areas. Because of low pressure and massive leakage (due to lack of endothelial cells), only a few red blood cells reached the 
glomeruli. N, When the human re‐endothelialized kidney scaffold was perfused with whole blood, high coverage of blood in the cortex was 
observed (shown in red), showing that perfusion of blood through the entire kidney was possible. O, Whereas the whole blood perfusion of 
the decellularized human kidney scaffold was stopped within 5 min because of extremely high perfusion pressures, the re‐endothelialized 
kidney could be perfused for more than 20 min. Scale bar B, C 500 μm; scale bar D, F, H 50 μm; scale bar E 25 μm. White arrowheads: CD31 
dynabead, black/white arrowhead: proliferating cell. Scale bar M, N 200 μm. hiPS‐ECs, human inducible pluripotent stem cell–derived 
endothelial cells; ns, nonsignificant
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hIPS‐ECs could be produced from patient‐derived cells, which will 
most likely reduce the need for immunosuppressant therapy. In 
addition, their proliferative potential, which was supported by the 
scaffold, was a key factor in achieving the scalability for re‐endo‐
thelialization of a human kidney scaffold. Obviously, maintenance 
of genomic integrity during reprogramming and subsequent ex‐
pansion together with improvements in the subsequent matura‐
tion of these cells into a safe transferable cellular phenotype will 
be critical aspects that need further development. This is the case 
for all proposed approaches for tissue bio‐engineering using plu‐
ripotent stem cells and is therefore at the center of attention in 
the stem cell field.
Next to the vascular compartment, the epithelial compart‐
ment of the kidney will also require successful recellularization in 
order to obtain a full functional bio‐engineered kidney. Song et al 
showed that, when a rat kidney scaffold was recellularized with 
neonatal rat kidney cells, site‐specific epithelial recellularization 
was observed.9 Whether hiPSC‐derived kidney progenitor cells3 
show the same potential or whether recellularization with distinct 
subtypes of hiPSC‐derived kidney epithelial cells will be required 
still needs further investigation.
5  | CONCLUSION
Here, we show that preservation of the GAG landscape and the pos‐
sibility to load the scaffold with growth factors such as VEGF and 
angiopoietin‐1 are critical to EC adherence and survival on a kidney 
scaffold. Using a new controlled arteriovenous delivery and culture 
method of hiPSC‐derived ECs, we report the re‐endothelialization of 
the kidney vasculature, including the glomerular and peritubular capil‐
laries. We show for the first time that this method is scalable toward 
the human kidney scaffold where perfusion with human whole blood 
could be achieved. These findings provide unique insight into a critical 
step to develop a human bioengineered kidney.
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